Skip to main content
SpringerLink
Log in

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

There is no standard salvage chemotherapy for relapsed or refractory peripheral T-cell lymphomas (PTCLs). Gemcitabine combined with cisplatin has been known as an effective regimen for lymphoma treatment in the salvage setting. We investigated the efficacy and toxicity of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory PTCLs in search of a more effective and less toxic therapy. Patients with relapsed or refractory PTCLs with more than one previous regimen were eligible. Treatment consisted of gemcitabine 1000 mg/m2 intravenously (i.v.) on days 1 and 8, dexamethasone 40 mg orally on days 1–4, and cisplatin 70 mg/m2 i.v. on day 1, and then every 21 days. Patients could proceed to autologous stem cell transplantation (ASCT) after four cycles of GDP or receive up to six treatment cycles. Twenty-five eligible patients were evaluated for toxicity and response. The diagnoses of participants included 14 cases of PTCL-not otherwise specified (NOS) (56 %) and four cases of angioimmunoblastic T-cell lymphoma (16 %) among others. The median age of the patients was 59 years (range 20–75 years). After treatments with GDP, which delivered a median of four GDP cycles, there were 12 patients with complete responses (CR; 48 %) and six with partial responses (PR; 24 %). The overall response rate (RR) was 72 %. Four patients preceded to ASCT, and three patients finally achieved CR. The median progression free survival was 9.3 months (95 % confidence interval (CI); 4.1–14.6) with a median follow-up duration of 27.1 months. In a total of 86 cycles of GDP, grade 3 or 4 neutropenia and thrombocytopenia occurred in 16.3 and 12.8 % of cycles, respectively. Three patients (3.3 %) experienced febrile neutropenia. GDP is a highly effective and optimal salvage regimen for relapsed or refractory PTCLs and can be administered with acceptable toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 38(1):75–81

    Article  CAS  PubMed  Google Scholar 

  2. Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM, Gonzalez M, Ribera JM, Brunet S, Garcia-Conde J, Fernandez de Sevilla A, Bosch F, Montserrat E (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 9(8):849–855

    Article  CAS  PubMed  Google Scholar 

  3. Reddy NM, Evens AM (2014) Chemotherapeutic advancements in peripheral T-cell lymphoma. Semin Hematol 51(1):17–24. doi:10.1053/j.seminhematol.2013.11.006

    Article  CAS  PubMed  Google Scholar 

  4. Yoon SO, Suh C, Lee DH, Chi HS, Park CJ, Jang SS, Shin HR, Park BH, Huh J (2010) Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol 85(10):760–764. doi:10.1002/ajh.21824

    Article  PubMed  Google Scholar 

  5. Sallah S, Wan JY, Nguyen NP (2001) Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113(1):185–187

    Article  CAS  PubMed  Google Scholar 

  6. Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P, Pileri SA, Tura S (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9(12):1351–1353

    Article  CAS  PubMed  Google Scholar 

  7. Yao YY, Tang Y, Zhu Q, Zhuang Y, Cheng YM, Wang L, Zou LF (2013) Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk Lymphoma 54(6):1194–1200. doi:10.3109/10428194.2012.739286

    Article  CAS  PubMed  Google Scholar 

  8. Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119(2):371–379. doi:10.1002/cncr.27733

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Zhong DT, Shi CM, Chen Q, Huang JZ, Liang JG (2012) Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin’s lymphoma. Ann Hematol 91(11):1757–1763. doi:10.1007/s00277-012-1518-y

    Article  CAS  PubMed  Google Scholar 

  10. Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, Solal-Celigny P, Sebban C, Coiffier B, Chouaki N, Bauters F, Dumontet C (2007) Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 18(2):370–375. doi:10.1093/annonc/mdl395

    Article  CAS  PubMed  Google Scholar 

  11. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106(2):353–360. doi:10.1002/cncr.21587

    Article  CAS  PubMed  Google Scholar 

  12. Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P (2004) Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 5(1):45–49

    Article  CAS  PubMed  Google Scholar 

  13. Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101(8):1835–1842. doi:10.1002/cncr.20587

    Article  CAS  PubMed  Google Scholar 

  14. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586. doi:10.1200/JCO.2006.09.2403

    Article  PubMed  Google Scholar 

  15. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92(8):1352–1357. doi:10.1038/sj.bjc.6602514

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Aviles A, Neri N, Huerta-Guzman J, Fernandez R (2004) Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology 66(3):197–200. doi:10.1159/000077995

    Article  CAS  PubMed  Google Scholar 

  17. Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21(4):860–863. doi:10.1093/annonc/mdp508

    Article  CAS  PubMed  Google Scholar 

  18. Evens A, Feldman T, Kroll A, Winer E, Flowers C, Lansigan F, Nabhan C, Nastoupil L, Kim A, Li X, Waksmundzki K (2012) Survival of newly diagnosed T-cell lymphoma (TCL) in the modern era: investigation of prognostic factors with critical examination of therapy in a multicenter US cohort. Blood (ASH Annual Meeting Abstracts) 120:2728a

    Google Scholar 

  19. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 32(31):3490–3496. doi:10.1200/JCO.2013.53.9593

    Article  CAS  PubMed  Google Scholar 

  20. Yim KL, Ashley S (2012) Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. Med Oncol 29(5):3535–3539. doi:10.1007/s12032-012-0309-6

    Article  CAS  PubMed  Google Scholar 

  21. Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271–272

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors indicate that they do not have any conflicts of interests.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

    Byeong-Bae Park

  2. Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, 50 Ilwon-dong, Kangnam-gu, Seoul, 135-710, Republic of Korea

    Won Seog Kim

  3. Department of Internal Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea

    Cheolwon Suh

  4. Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical sciences, Seoul, Korea

    Dong-Yeop Shin

  5. Division of Hematology, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, Catholic University of Korea, Suwon, Korea

    Jeong-A Kim

  6. Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju, Korea

    Hoon-Gu Kim

  7. Division of Hematology, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea

    Won Sik Lee

Authors
  1. Byeong-Bae Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Won Seog Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheolwon Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dong-Yeop Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeong-A Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hoon-Gu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Won Sik Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Won Seog Kim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Park, BB., Kim, W.S., Suh, C. et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol 94, 1845–1851 (2015). https://doi.org/10.1007/s00277-015-2468-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2468-y

Keywords

Search

Navigation